KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Common Equity (2019 - 2025)

Historic Common Equity for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $600.7 million.

  • GoodRx Holdings' Common Equity fell 1374.46% to $600.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $600.7 million, marking a year-over-year decrease of 1374.46%. This contributed to the annual value of $724.7 million for FY2024, which is 489.53% down from last year.
  • Per GoodRx Holdings' latest filing, its Common Equity stood at $600.7 million for Q3 2025, which was down 1374.46% from $643.0 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Common Equity registered a high of $895.4 million during Q2 2023, and its lowest value of $600.7 million during Q3 2025.
  • Over the past 5 years, GoodRx Holdings' median Common Equity value was $786.5 million (recorded in 2022), while the average stood at $760.3 million.
  • Per our database at Business Quant, GoodRx Holdings' Common Equity skyrocketed by 18029.28% in 2021 and then plummeted by 2523.78% in 2024.
  • Over the past 5 years, GoodRx Holdings' Common Equity (Quarter) stood at $831.7 million in 2021, then decreased by 2.03% to $814.8 million in 2022, then fell by 6.49% to $762.0 million in 2023, then dropped by 4.9% to $724.7 million in 2024, then dropped by 17.1% to $600.7 million in 2025.
  • Its Common Equity stands at $600.7 million for Q3 2025, versus $643.0 million for Q2 2025 and $654.3 million for Q1 2025.